The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 10 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Deming: Longevity is counterintuitively the least risky sector in biology
“I literally thought it was the least risky, most likely to work part of biology in general, particularly the part of biology that would be easy to test in humans, and that's very counterintuitive to most people.”
Deming: Biotech VC is constrained by founder talent, not funding
“And so I think the fascinating thing is, you know, I always assumed from the outside that biotech venture capital was really limited by dollars, and I think it used to be, but I think the fascinating fact is now it's all about talent, and just, you know, we're…”
Deming: Biotech value stems from founder-driven decisions, not initial thesis
“And I think, you know, maybe sometimes focusing on the thesis of an investment can blind you to the fact that most of the value in biotech comes from the eventual trajectory of the company that's unpredictable at the start. And that trajectory is absolutely di…”
Deming: Biotech VC funding doubled while new startup creation remained flat
“I think one of the founding into biotech venture capital has doubled over the past couple years, and that's a huge fact, but the number of companies started to stay fairly stable”
Deming: All Longevity Fund portfolio companies target multi-disease pathways
“All the companies that we invest in have drugs that have worked not just in kind of mouse models of Alzheimer's typically, but also diabetes and heart disease, and kind of typically the pathways that we invest in have been tested in and work in almost every Ag…”
Deming: VC value creation is limited by rigid fund structure norms
“I think the diversity of fun types. I think we've been artificially constrained by a perception that it's hard to raise a new structure of fun because LPs just kind of, like, amorphously won't like it. I think that's really cut down on the value to be created …”
Laura Deming: Three decades of research prove aging is genetically malleable
“There was really very little work on aging and longevity, but the past three decades have resulted in massive advances. So we now know that it's possible to genetically control aging, that aging is malleable.”
Deming: Internal biotech studio builds yield higher equity and easier LP pitches
“I mean, I think it's a great strategy. It's great for the VCs for certain parameters. I think the likelihood of success is slightly higher. The equity stakes are definitely higher, and there's a better pitch to LPs in the short term.”